Read this company snapshot
Daily valuation snapshot
Apollomics Inc. Class A Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $21.5
- Market capitalization (USD)
- $62,671,747.5
- Price / earnings (TTM)
- Not reported
- Price / book
- Not reported
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research APLM in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research APLM in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing APLM with another company.
| Daily close (USD) | $21.5 |
| Market capitalization (USD) | $62,671,747.5 |
| Price / earnings (TTM) | Not reported |
| Price / book | Not reported |
No matching rows. Clear the filter to see all records.
Read APLM's valuation metrics
Company size
Apollomics Inc. Class A Ordinary Shares's recorded market capitalization is $62,671,747.5. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
Price-to-book compares market equity value with recorded book equity. Intangible assets, profitability and the company's business affect how useful the comparison is.
Research Apollomics Inc. Class A Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about APLM. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow APLM's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.